Remove tag revenue
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

If the drug is approved you can bet that it’s going to carry a huge price tag. Biogen needs a new drug revenue badly. It could carry a price tag as high as $50,000-a-year per patient, according to drug analysts, adding billions of dollars to the nation’s health tab. .

Drugs 187
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.

Drugs 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Medicare savings won’t make a dent in healthcare costs

World of DTC Marketing

Still, in a JAMA study, the median net income (earnings) expressed as a fraction of revenue was significantly greater for pharmaceutical companies than nonpharmaceutical companies (13.8% The drug industry is trying to convince voters that government negotiations with drug companies will lead to less innovation.

Drugs 222
article thumbnail

Dynamic Reports – A How-to Guide

Cloudbyz

Now, here comes a scenario where your senior account manager wants to view a report of all the opportunities and their respective stages along with forecasted and actual revenue for a particular account. Salesforce uses these UI tags: fv0 , fv1 , fv2 for custom filters added after standard filters in URLs to run the report.

article thumbnail

Biogen’s Aduhelm rollout goes from bad to worse

pharmaphorum

Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. That dragged down Biogen’s overall revenues, which fell 18% to $2.2 billion, with Tecfidera’s decline offset in part by gains for follow-up drug Vumerity (diroximel fumarate), which brought in $121 million.

Sales 118
article thumbnail

Lyfgenia and Casgevy Become First FDA-Approved Gene Therapies for Sickle Cell Disease

XTalks

Obenshain said the company will book revenue when the final product is infused, and that the product manufacturing could take 70 to 105 days. Analysts at Cantor explained that Vertex only has nine centers for Casgevy, including six that also offer Lyfgenia. Vertex-CRISPR’s Casgevy has a US list price of $2.2

article thumbnail

Gilead tags Merck for first-line triple negative breast cancer trial

pharmaphorum

While its headline revenue of $7.4 The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on. Analysts welcomed the performance but also noted it points to underlying weakness at the company. billion was a healthy 13% rise, taking Veklury out of the equation would have resulted in a 3% decline.

Trials 52